Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Long-Term Engraftment of Human Cardiomyocytes Combined with Biodegradable Microparticles Induces Heart Repair.

Saludas L, Garbayo E, Mazo M, Pelacho B, Abizanda G, Iglesias-Garcia O, Raya A, Prósper F, Blanco-Prieto MJ.

J Pharmacol Exp Ther. 2019 Sep;370(3):761-771. doi: 10.1124/jpet.118.256065. Epub 2019 Feb 6.

PMID:
30728248
2.

Advances in Parkinson's Disease: 200 Years Later.

Del Rey NL, Quiroga-Varela A, Garbayo E, Carballo-Carbajal I, Fernández-Santiago R, Monje MHG, Trigo-Damas I, Blanco-Prieto MJ, Blesa J.

Front Neuroanat. 2018 Dec 14;12:113. doi: 10.3389/fnana.2018.00113. eCollection 2018. Review.

3.

Micro- and nanotechnology approaches to improve Parkinson's disease therapy.

Torres-Ortega PV, Saludas L, Hanafy AS, Garbayo E, Blanco-Prieto MJ.

J Control Release. 2019 Feb 10;295:201-213. doi: 10.1016/j.jconrel.2018.12.036. Epub 2018 Dec 21. Review.

PMID:
30579984
4.

NRG1 PLGA MP locally induce macrophage polarisation toward a regenerative phenotype in the heart after acute myocardial infarction.

Pascual-Gil S, Abizanda G, Iglesias E, Garbayo E, Prósper F, Blanco-Prieto MJ.

J Drug Target. 2019 Jun - Jul;27(5-6):573-581. doi: 10.1080/1061186X.2018.1531417. Epub 2018 Oct 17.

PMID:
30289743
5.

Heart tissue repair and cardioprotection using drug delivery systems.

Saludas L, Pascual-Gil S, Roli F, Garbayo E, Blanco-Prieto MJ.

Maturitas. 2018 Apr;110:1-9. doi: 10.1016/j.maturitas.2018.01.011. Epub 2018 Jan 13. Review.

PMID:
29563026
6.

Special issue on biomaterials for tissue engineering.

Blanco-Prieto MJ, Garbayo E.

Int J Pharm. 2017 May 25;523(2):439-440. doi: 10.1016/j.ijpharm.2017.02.040. Epub 2017 Feb 20. No abstract available.

PMID:
28219633
7.

Transplantation of adipose-derived stem cells combined with neuregulin-microparticles promotes efficient cardiac repair in a rat myocardial infarction model.

Díaz-Herráez P, Saludas L, Pascual-Gil S, Simón-Yarza T, Abizanda G, Prósper F, Garbayo E, Blanco-Prieto MJ.

J Control Release. 2017 Mar 10;249:23-31. doi: 10.1016/j.jconrel.2017.01.026. Epub 2017 Jan 19.

PMID:
28111317
8.

Hydrogel based approaches for cardiac tissue engineering.

Saludas L, Pascual-Gil S, Prósper F, Garbayo E, Blanco-Prieto M.

Int J Pharm. 2017 May 25;523(2):454-475. doi: 10.1016/j.ijpharm.2016.10.061. Epub 2016 Oct 29. Review.

PMID:
27989830
9.

Development and characterization of polo-like kinase 2 loaded nanoparticles-A novel strategy for (serine-129) phosphorylation of alpha-synuclein.

Rodríguez-Nogales C, Garbayo E, Martínez-Valbuena I, Sebastián V, Luquin MR, Blanco-Prieto MJ.

Int J Pharm. 2016 Nov 30;514(1):142-149. doi: 10.1016/j.ijpharm.2016.06.044.

PMID:
27863657
10.

Cytokine-loaded PLGA and PEG-PLGA microparticles showed similar heart regeneration in a rat myocardial infarction model.

Pascual-Gil S, Simón-Yarza T, Garbayo E, Prósper F, Blanco-Prieto MJ.

Int J Pharm. 2017 May 25;523(2):531-533. doi: 10.1016/j.ijpharm.2016.11.022. Epub 2016 Nov 9.

PMID:
27838293
11.

Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys.

Garbayo E, Ansorena E, Lana H, Carmona-Abellan MD, Marcilla I, Lanciego JL, Luquin MR, Blanco-Prieto MJ.

Biomaterials. 2016 Dec;110:11-23. doi: 10.1016/j.biomaterials.2016.09.015. Epub 2016 Sep 21.

PMID:
27697668
12.

Catheter-based Intramyocardial Injection of FGF1 or NRG1-loaded MPs Improves Cardiac Function in a Preclinical Model of Ischemia-Reperfusion.

Garbayo E, Gavira JJ, de Yebenes MG, Pelacho B, Abizanda G, Lana H, Blanco-Prieto MJ, Prosper F.

Sci Rep. 2016 May 17;6:25932. doi: 10.1038/srep25932.

13.

Brain aging and Parkinson's disease: New therapeutic approaches using drug delivery systems.

Rodríguez-Nogales C, Garbayo E, Carmona-Abellán MM, Luquin MR, Blanco-Prieto MJ.

Maturitas. 2016 Feb;84:25-31. doi: 10.1016/j.maturitas.2015.11.009. Epub 2015 Nov 21. Review.

14.

Tracking the in vivo release of bioactive NRG from PLGA and PEG-PLGA microparticles in infarcted hearts.

Pascual-Gil S, Simón-Yarza T, Garbayo E, Prosper F, Blanco-Prieto MJ.

J Control Release. 2015 Dec 28;220(Pt A):388-396. doi: 10.1016/j.jconrel.2015.10.058. Epub 2015 Nov 9.

PMID:
26546270
15.

Survival, differentiation, and neuroprotective mechanisms of human stem cells complexed with neurotrophin-3-releasing pharmacologically active microcarriers in an ex vivo model of Parkinson's disease.

Daviaud N, Garbayo E, Sindji L, Martínez-Serrano A, Schiller PC, Montero-Menei CN.

Stem Cells Transl Med. 2015 Jun;4(6):670-84. doi: 10.5966/sctm.2014-0139. Epub 2015 Apr 29.

16.

Heart regeneration after myocardial infarction using synthetic biomaterials.

Pascual-Gil S, Garbayo E, Díaz-Herráez P, Prosper F, Blanco-Prieto MJ.

J Control Release. 2015 Apr 10;203:23-38. doi: 10.1016/j.jconrel.2015.02.009. Epub 2015 Feb 7. Review.

PMID:
25665866
17.

Diagnostic and therapeutic uses of nanomaterials in the brain.

Garbayo E, Estella-Hermoso de Mendoza A, Blanco-Prieto MJ.

Curr Med Chem. 2014;21(36):4100-31. Review.

18.

Controlled delivery of fibroblast growth factor-1 and neuregulin-1 from biodegradable microparticles promotes cardiac repair in a rat myocardial infarction model through activation of endogenous regeneration.

Formiga FR, Pelacho B, Garbayo E, Imbuluzqueta I, Díaz-Herráez P, Abizanda G, Gavira JJ, Simón-Yarza T, Albiasu E, Tamayo E, Prósper F, Blanco-Prieto MJ.

J Control Release. 2014 Jan 10;173:132-9. doi: 10.1016/j.jconrel.2013.10.034. Epub 2013 Nov 5.

19.

Modeling nigrostriatal degeneration in organotypic cultures, a new ex vivo model of Parkinson's disease.

Daviaud N, Garbayo E, Lautram N, Franconi F, Lemaire L, Perez-Pinzon M, Montero-Menei CN.

Neuroscience. 2014 Jan 3;256:10-22. doi: 10.1016/j.neuroscience.2013.10.021. Epub 2013 Oct 23.

20.

Adipose-derived stem cells combined with neuregulin-1 delivery systems for heart tissue engineering.

Díaz-Herráez P, Garbayo E, Simón-Yarza T, Formiga FR, Prosper F, Blanco-Prieto MJ.

Eur J Pharm Biopharm. 2013 Sep;85(1):143-50. doi: 10.1016/j.ejpb.2013.03.022.

21.

Organotypic cultures as tools for optimizing central nervous system cell therapies.

Daviaud N, Garbayo E, Schiller PC, Perez-Pinzon M, Montero-Menei CN.

Exp Neurol. 2013 Oct;248:429-40. doi: 10.1016/j.expneurol.2013.07.012. Epub 2013 Jul 27. Review.

PMID:
23899655
22.

Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.

Garbayo E, Ansorena E, Blanco-Prieto MJ.

Maturitas. 2013 Nov;76(3):272-8. doi: 10.1016/j.maturitas.2013.05.019. Epub 2013 Jul 1. Review.

23.

Biodegradation and heart retention of polymeric microparticles in a rat model of myocardial ischemia.

Formiga FR, Garbayo E, Díaz-Herráez P, Abizanda G, Simón-Yarza T, Tamayo E, Prósper F, Blanco-Prieto MJ.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):665-72. doi: 10.1016/j.ejpb.2013.02.017. Epub 2013 Mar 21.

24.

Brain drug delivery systems for neurodegenerative disorders.

Garbayo E, Ansorena E, Blanco-Prieto MJ.

Curr Pharm Biotechnol. 2012 Sep;13(12):2388-402. Review.

PMID:
23016644
25.

A simple and efficient method for the production of human glycosylated glial cell line-derived neurotrophic factor using a Semliki Forest virus expression system.

Ansorena E, Casales E, Aranda A, Tamayo E, Garbayo E, Smerdou C, Blanco-Prieto MJ, Aymerich MS.

Int J Pharm. 2013 Jan 2;440(1):19-26. doi: 10.1016/j.ijpharm.2012.04.071. Epub 2012 May 1.

26.

Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease.

Garbayo E, Ansorena E, Lanciego JL, Blanco-Prieto MJ, Aymerich MS.

Mov Disord. 2011 Aug 15;26(10):1943-7. doi: 10.1002/mds.23793. Epub 2011 Jun 9.

PMID:
21661048
27.

Neuroprotective properties of marrow-isolated adult multilineage-inducible cells in rat hippocampus following global cerebral ischemia are enhanced when complexed to biomimetic microcarriers.

Garbayo E, Raval AP, Curtis KM, Della-Morte D, Gomez LA, D'Ippolito G, Reiner T, Perez-Stable C, Howard GA, Perez-Pinzon MA, Montero-Menei CN, Schiller PC.

J Neurochem. 2011 Dec;119(5):972-88. doi: 10.1111/j.1471-4159.2011.07272.x. Epub 2011 May 13.

28.

The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats.

Delcroix GJ, Garbayo E, Sindji L, Thomas O, Vanpouille-Box C, Schiller PC, Montero-Menei CN.

Biomaterials. 2011 Feb;32(6):1560-73. doi: 10.1016/j.biomaterials.2010.10.041. Epub 2010 Nov 12.

29.

EF1alpha and RPL13a represent normalization genes suitable for RT-qPCR analysis of bone marrow derived mesenchymal stem cells.

Curtis KM, Gomez LA, Rios C, Garbayo E, Raval AP, Perez-Pinzon MA, Schiller PC.

BMC Mol Biol. 2010 Aug 17;11:61. doi: 10.1186/1471-2199-11-61.

30.

Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model.

Formiga FR, Pelacho B, Garbayo E, Abizanda G, Gavira JJ, Simon-Yarza T, Mazo M, Tamayo E, Jauquicoa C, Ortiz-de-Solorzano C, Prósper F, Blanco-Prieto MJ.

J Control Release. 2010 Oct 1;147(1):30-7. doi: 10.1016/j.jconrel.2010.07.097. Epub 2010 Jul 17.

31.

Production of highly pure human glycosylated GDNF in a mammalian cell line.

Ansorena E, Garbayo E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ.

Int J Pharm. 2010 Jan 29;385(1-2):6-11. doi: 10.1016/j.ijpharm.2009.10.015. Epub 2009 Oct 13.

32.

Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease.

Garbayo E, Montero-Menei CN, Ansorena E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ.

J Control Release. 2009 Apr 17;135(2):119-26. doi: 10.1016/j.jconrel.2008.12.010. Epub 2008 Dec 25.

33.

Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres.

Garbayo E, Ansorena E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ.

Eur J Pharm Biopharm. 2008 Aug;69(3):844-51. doi: 10.1016/j.ejpb.2008.02.015. Epub 2008 Feb 23.

34.

Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor.

Garbayo E, Ansorena E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ.

Int J Pharm. 2007 Nov 1;344(1-2):9-15. Epub 2007 Apr 6.

35.

[Neuroprotective and neurorestorative therapies for the treatment of Parkinson's disease].

Garbayo E, Aymerich MS, Ansorena E, Lanciego JL, Blanco-Prieto MJ.

An Sist Sanit Navar. 2006 Sep-Dec;29(3):325-35. Review. Spanish.

Supplemental Content

Loading ...
Support Center